Scientists revisit recent findings on how different hormone therapy treatments influence the likelihood of developing Parkinson's in women

The question of how hormone replacement therapy affects brain health has sparked intense debate among researchers for decades. A major review published in the journal Neurological Sciences analysed fourteen global studies involving more than seven hundred and fifty thousand women. Its findings suggested that the specific recipe of hormones matters greatly. While taking oestrogen on its own showed no increased chance of developing Parkinson's, combined therapy containing both oestrogen and progestogen appeared to be associated with a higher likelihood. Now, a formal letter to the editor published on 25 August 2026 has opened up this conversation, urging researchers and clinicians to look closer at what the data actually tells us before drawing firm conclusions. The initial review brought forward an important observation. When women took oestrogen by itself, their rates of Parkinson's remained entirely comparable to those who took no hormones at all. However, when progestogen was added to the regimen, the statistical models pointed towards an elevated risk of roughly thirty to forty per cent. This naturally led to questions about whether progestogens could have distinct biological effects inside the nervous system. The newly published response highlights several critical nuances that must be weighed when evaluating these findings. Most of the available evidence comes from observational studies, which track people in everyday life rather than testing treatments in tightly controlled laboratory trials. Because of this, it is exceptionally difficult to separate the effects of the medication from the reasons a woman was prescribed that specific combination in the first place. For instance, combined hormone therapy is typically prescribed to women who still have their womb to protect against uterine changes, whereas oestrogen only therapy is generally reserved for women who have had a hysterectomy. Surgical removal of the ovaries and womb changes the body's natural hormone environment in unique ways, making the two groups inherently different even before their first prescription is written. Timing and duration also play a massive role. Hormones behave differently depending on whether someone starts them right at the start of menopause or years later. The original meta analysis pooled together studies that used varying doses, different chemical types of progestogens, and different lengths of treatment. When all these variations are grouped together, subtle patterns can be exaggerated or blurred. Statistically, the authors of the critique point out that while combined therapy crossed the threshold for higher risk on its own, the mathematical difference between the two treatments was not distinct enough to declare them fundamentally opposite. In simple terms, while the numbers hint at a divergence, the evidence is not yet conclusive enough to prove that combined therapy directly causes harm to dopamine producing areas of the brain. For women weighing the benefits of hormone therapy for menopausal symptoms and bone strength, the takeaway is clear and grounded. Rather than cause for panic, this ongoing scientific exchange represents healthy medical debate in action. It underlines the importance of looking at personal health history rather than treating all hormone formulations as identical, while paving the way for more detailed clinical research into how individual hormones interact with long term brain health.